Last reviewed · How we verify
Ebglyss (LEBRIKIZUMAB)
Ebglyss (generic name: LEBRIKIZUMAB) is a Interleukin-13 Antagonist [EPC] Monoclonal antibody drug developed by Eli Lilly And Co. It is currently FDA-approved (first approved 2025) for Moderate-to-severe atopic dermatitis.
Ebglyss works by binding to interleukin-13, a protein that promotes inflammation in the skin.
Lebrikizumab, also known as Ebgliss, is an interleukin-13 inhibitor, a type of antibody that targets the Interleukin-13 protein. It is being studied for its potential to treat conditions such as atopic dermatitis and eczema, as well as to improve health-related well-being in individuals with moderate-to-severe atopic dermatitis.
At a glance
| Generic name | LEBRIKIZUMAB |
|---|---|
| Sponsor | Eli Lilly And Co |
| Drug class | Interleukin-13 Antagonist [EPC] |
| Modality | Monoclonal antibody |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2025 |
Mechanism of action
Lebrikizumab-lbkz is an IgG4 monoclonal antibody that binds with high affinity and slow off-rate to interleukin (IL)-13 and allows IL-13 to bind to IL-13Rα1 but inhibits human IL-13 signaling through the IL-4Rα/IL-13Rα1 receptor complex. IL-13 is a naturally occurring cytokine that is involved in Type 2 inflammation, which is an important component in the pathogenesis of atopic dermatitis. Lebrikizumab-lbkz inhibits IL-13-induced responses including the release of proinflammatory cytokines, chemokines and IgE. Lebrikizumab-lbkz-bound IL-13 can still bind IL-13Rα2 allowing subsequent internalization and natural clearance of IL-13.
Approved indications
- Moderate-to-severe atopic dermatitis
Common side effects
- Conjunctivitis
- Injection Site Reactions
- Herpes Zoster
Key clinical trials
- A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) (PHASE3)
- A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) (PHASE3)
- A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden (PHASE4)
- A Study of LAD106 in Healthy Adult Participants (PHASE1)
- A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color (PHASE3)
- A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis (PHASE3)
- A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab (PHASE3)
- A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ebglyss CI brief — competitive landscape report
- Ebglyss updates RSS · CI watch RSS
- Eli Lilly And Co portfolio CI
Frequently asked questions about Ebglyss
What is Ebglyss?
How does Ebglyss work?
What is Ebglyss used for?
Who makes Ebglyss?
What is the generic name of Ebglyss?
What drug class is Ebglyss in?
When was Ebglyss approved?
What development phase is Ebglyss in?
What are the side effects of Ebglyss?
Related
- Drug class: All Interleukin-13 Antagonist [EPC] drugs
- Manufacturer: Eli Lilly And Co — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Moderate-to-severe atopic dermatitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing